drugset / Trial / NCT04256213
COL Immunotherapy Before Radiochimio + Ipilimumab
NaSingle-groupOpen-labelOther
Summary
This is a multicenter, single arm pilot study evaluating the biological impact of "Nivolumab + Ipilimumab" in patients with cervical squamous cell carcinoma requiring RT-CT as initial therapy
Timeline
- Start
- 2020-07-02
- Primary completion
- 2021-08-30
- Completion
- 2024-08-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ipilimumab | Monoclonal antibody | 1 mg/kg | Intravenous |
| Subject | Nivolumab | Monoclonal antibody | 480 mg | Intravenous |